Drugs / Erythrocyte-αPD-1 conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06528249 | Jul 2024 → Jul 2026 overdue | cancer, hematopoietic and lymphoid cell neoplasm | Zhejiang Provincial People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erythrocyte-αPD-1 conjugate | “Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies” NCT06528249 ↗ |
| Modality | Cell therapy | “Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes” NCT06528249 ↗ |